Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Course Regimens for Drug-Susceptible Pulmonary Tuberculosis in AIDS Patients
NCT07608172Not yet recruiting
- Start
- May 2026
- Primary completion
- Jun 2028
01
Overview
Randomised, open-label trial of isoniazid, rifapentine, moxifloxacin and pyrazinamide in pulmonary tuberculosis (TB) (2 arms). Primary endpoint: All-cause mortality at 12 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
isoniazidrifapentinemoxifloxacinpyrazinamide
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT07608172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608172.